Sangamo Therapeutics Cash Flow Statement

Financials in millions USD. Fiscal year is January - December.

Millions USD. Fiscal year is Jan - Dec.

Year Ending	TTM	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021	Dec 31, 2020	Dec 31, 2019	2018 - 1997
Net Income	-328.05	-257.83	-192.28	-178.29	-121	-95.19	Upgrade
Depreciation & Amortization	19.14	22.19	20.56	17.64	13.37	9.61	Upgrade
Share-Based Compensation	21.81	27.36	31.65	32.96	25.71	19.33	Upgrade
Other Operating Activities	79.91	-16.57	-83.56	-105.56	251.79	-78.15	Upgrade
Operating Cash Flow	-207.21	-224.84	-223.63	-233.25	169.88	-144.4	Upgrade
Capital Expenditures	-10.96	-21.16	-20.17	-23.28	-14.71	-20.68	Upgrade
Acquisitions	0	0	0	-0.12	-0.7	-0.26	Upgrade
Change in Investments	164.6	174.69	79.46	271.6	-256.21	-38.86	Upgrade
Investing Cash Flow	153.64	153.53	59.29	248.2	-271.63	-59.8	Upgrade
Share Issuance / Repurchase	29.45	16.04	86.76	36.12	153.87	142.45	Upgrade
Other Financing Activities	-0.75	-1.45	-2.1	-3.26	-0.77	-0.42	Upgrade
Financing Cash Flow	28.71	14.59	84.66	32.86	153.1	142.03	Upgrade
Exchange Rate Effect	0.45	1.48	1.25	-0.26	-0.45	0.18	Upgrade
Net Cash Flow	-24.41	-55.24	-78.43	47.54	50.9	-61.99	Upgrade
Free Cash Flow	-218.16	-246	-243.8	-256.53	155.16	-165.08	Upgrade
Free Cash Flow Margin	-1163.15%	-139.59%	-219.05%	-231.73%	131.28%	-161.16%	Upgrade
Free Cash Flow Per Share	-1.21	-1.41	-1.58	-1.77	1.15	-1.47	Upgrade

Source: Financials are provided by Nasdaq Data Link and sourced from the audited annual (10-K) and quarterly (10-Q) reports submitted to the Securities and Exchange Commission (SEC).